Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

751 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Towards interactive AI-authoring with prototypical few-shot classifiers in histopathology.
Kuritcyn P, Kletzander R, Eisenberg S, Wittenberg T, Bruns V, Evert K, Keil F, Ziegler PK, Bankov K, Wild P, Eckstein M, Hartmann A, Geppert CI, Benz M. Kuritcyn P, et al. Among authors: eckstein m. J Pathol Inform. 2024 Jun 6;15:100388. doi: 10.1016/j.jpi.2024.100388. eCollection 2024 Dec. J Pathol Inform. 2024. PMID: 39712980 Free PMC article.
Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer.
Otto W, van Rhijn BW, Breyer J, Bertz S, Eckstein M, Mayr R, Lausenmeyer EM, Denzinger S, Burger M, Hartmann A. Otto W, et al. Among authors: eckstein m. Int J Urol. 2018 May;25(5):442-449. doi: 10.1111/iju.13532. Epub 2018 Feb 22. Int J Urol. 2018. PMID: 29473226
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F. Eckstein M, et al. Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5. Eur J Cancer. 2019. PMID: 30528808
Co-staining of microRNAs and their target proteins by miRNA in situ hybridization and immunohistofluorescence on prostate cancer tissue microarrays.
Eckstein M, Sailer V, Nielsen BS, Wittenberg T, Wiesmann V, Lieb V, Nolte E, Hartmann A, Kristiansen G, Wernert N, Wullich B, Taubert H, Wach S; German Prostate Cancer Consortium (DPKK). Eckstein M, et al. Lab Invest. 2019 Oct;99(10):1527-1534. doi: 10.1038/s41374-019-0251-8. Epub 2019 Jun 11. Lab Invest. 2019. PMID: 31186527 Free article.
CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage.
Eckstein M, Epple E, Jung R, Weigelt K, Lieb V, Sikic D, Stöhr R, Geppert C, Weyerer V, Bertz S, Kehlen A, Hartmann A, Wullich B, Taubert H, Wach S. Eckstein M, et al. Cancers (Basel). 2020 May 15;12(5):1253. doi: 10.3390/cancers12051253. Cancers (Basel). 2020. PMID: 32429318 Free PMC article.
Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy.
Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz R, Pfannstiel C, Wullweber A, Lange F, Erben P, Stoehr R, Bertz S, Geppert CI, Fuhrich N, Taubert H, Wach S, Breyer J, Otto W, Burger M, Bolenz C, Keck B, Wullich B, Hartmann A, Sikic D; BRIDGE Consortium e.V., Mannheim, Germany. Eckstein M, et al. J Immunother Cancer. 2020 May;8(1):e000162. doi: 10.1136/jitc-2019-000162. J Immunother Cancer. 2020. PMID: 32448798 Free PMC article.
751 results